Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Research Review

Showing 1–3 of 3 articles · Keyword: osteoarthritis Clear keyword

Journal of orthopaedic translation2026ReviewNon-viral Gene DeliveryDrug Delivery

1. Nanoparticle delivery systems for gene therapy of degenerative musculoskeletal diseases

Chen X, Sun J, Xie W, Arthur Vithran Dt, Zhang Q, Rosenholm Jm, Et Al.

Degenerative musculoskeletal diseases (DMDs) are a group of chronic conditions characterized by the progressive deterioration of tissue structure and function, primarily affecting the articular cartilage, bones, tendons, and ligaments. With global aging populations, the rising prevalence of these disorders presents a…

Read the article

Viruses2026ReviewNon-viral Gene Delivery

2. Gene Therapy for Osteoarthritis: Viral and Non-Viral Delivery Strategies

Zhang M, Mohess J, Cheung J, Du Q, Qiu J, Wang J

Osteoarthritis (OA) is the most prevalent joint disease, which is pathologically characterized by articular cartilage degradation, chronic synovial inflammation, subchondral bone remodeling, and osteophyte formation. Patients with OA suffer from joint pain, deformity, and functional impairment. Current therapies…

Read the article

International journal of pharmaceutics2026ResearchNon-viral Gene DeliveryDrug Delivery

3. Machine learning-guided chondrocyte membrane-camouflaged lipid nanoparticles for intra-articular SOX9 mRNA therapy of osteoarthritis

Li J, Li C, Wang H, Yu H, Zhang T, Li C, Et Al.

Osteoarthritis (OA) progression involves cartilage matrix loss and persistent inflammation. This study developed a machine learning-guided and chondrocyte membrane-camouflaged lipid nanoparticle carrying messenger RNA (CM-LNP@mRNA) platform for intra-articular SOX9 delivery. Random forest analysis identified the…

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.